De Amici Marco, Conti Paola, Fasoli Ezio, Barocelli Elisabetta, Ballabeni Vigilio, Bertoni Simona, Impicciatore Mariannina, Roth Bryan L, Ernsberger Paul, De Micheli Carlo
Istituto di Chimica Farmaceutica e Tossicologica, Università di Milano, Viale Abruzzi 42, Milan 20131, Italy.
Farmaco. 2003 Sep;58(9):739-48. doi: 10.1016/S0014-827X(03)00113-7.
A set of novel heterocyclic ligands (7a-9a, 7b-9b, and 9c) structurally related to oxotremorine 2 was designed, synthesized, and tested at muscarinic receptor subtypes. In the binding experiments at cloned hm1-5, the presence of the 2-methylimidazole/2-methyl-3-alkylimidazolium moiety in place of the pyrrolidine ring revealed, in derivatives 8a, 8b, and 9c, a moderate selectivity for some receptor subtypes. The functional in vitro assays yielded results that correlated closely to binding data. In general, on passing from agonists bearing the pyrrolidine moiety to their analogues carrying the 2-methylimidazole function, the overall pharmacological efficacy profile is shifted from agonism toward partial agonism. The insertion of the 2-methyl-3-alkylimidazolium moiety advances the effect such that the compounds are pure antagonists. Quite similarly, chiral 3-oxo-Delta(2)-isoxazoline (+/-)-10 behaved as a weak antagonist unable to discriminate the different muscarinic receptor subtypes.
